309 research outputs found
Recommended from our members
International studies on burnup credit criticality safety by an OECD/NEA working group
The results and conclusions from a six-year study by an international benchmarking group in the comparison of computational methods for evaluating burnup credit in criticality safety analyses is presented. Approximately 20 participants from 12 countries have provided results for most problems. Four detailed benchmark problems for pressurized-water-reactor fuel have been completed. Results from work being finalized, addressing burnup credit for boiling-water-reactor fuel, are discussed, as well as planned activities for additional benchmarks, including mixed-oxide fuels, and other activities
Novel microbiological system for antibiotic detection in ovine milk
[EN] This article presents a microbiological system composed of a " BT" bioassay (Beta-lactams and Tetracyclines) and a " QS" bioassay (Quinolones and Sulfonamides). The " BT" bioassay contains spores of Geobacillus stearothermophilus, bromocresol purple and cloramphenicol in a culture medium (incubation time: 2.45h), while the " QS" bioassay uses spores of Bacillus subtilis, trifenyltetrazolium - toluidine blue and trimethoprim in a suitable culture medium (incubation time: 5.5h). The detection capability (CC ß) of 27 antimicrobial agents in ovine milk were determined by logistic regression models. Thus, the " BT" bioassay detects amoxycillin, ampicillin, penicillin " G" , cloxacillin, oxacillin, cephalexin, cefoperazone, ceftiofur, chlortetracycline, oxytetracycline, tetracycline, neomycin, gentamycin and tylosin, while " QS" bioassay detects: ciprofloxacin, enrofloxacin, marbofloxacin, sulfadiazine, sulfadimethoxine, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfathiazole, erythromycin, lincomycin and spiramycin at levels close to their respective Maximum Residue Limits. The simultaneous use of both bioassays detects a large number of antibiotics in milk given each method's adequate complementary sensitivity. © 2011 Elsevier B.V..This research work has been carried out as part of the CAI+D'09/12 Projects (No. 033-173 Res. H.C.D. No. 100/09, Universidad Nacional del Litoral, Santa Fe, Argentina) and AGL2009-11524 (Ministry of Science and Innovation, Spain).Nagel, OG.; Beltrán Martínez, MC.; Molina Pons, MP.; Lisandro Althaus, R. (2012). Novel microbiological system for antibiotic detection in ovine milk. Small Ruminant Research. 102(1):26-31. https://doi.org/10.1016/j.smallrumres.2011.11.018S2631102
Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke : an economic evaluation
Objective:
To examine the cost-effectiveness of self-managed computerised word finding therapy as an add-on to usual care for people with aphasia post-stroke.
Design:
Cost-effectiveness modelling over a life-time period, taking a UK National Health Service (NHS) and personal social service perspective.
Setting:
Based on the Big CACTUS randomised controlled trial, conducted in 21 UK NHS speech and language therapy departments.
Participants:
Big CACTUS included 278 people with long-standing aphasia post-stroke.
Interventions:
Computerised word finding therapy plus usual care; usual care alone; usual care plus attention control.
Main measures:
Incremental cost-effectiveness ratios (ICER) were calculated, comparing the cost per quality adjusted life year (QALY) gained for each intervention. Credible intervals (CrI) for costs and QALYs, and probabilities of cost-effectiveness, were obtained using probabilistic sensitivity analysis. Subgroup and scenario analyses investigated cost-effectiveness in different subsets of the population, and the sensitivity of results to key model inputs.
Results:
Adding computerised word finding therapy to usual care had an ICER of £42,686 per QALY gained compared with usual care alone (incremental QALY gain: 0.02 per patient (95% CrI: −0.05 to 0.10); incremental costs: £732.73 per patient (95% CrI: £674.23 to £798.05)). ICERs for subgroups with mild or moderate word finding difficulties were £22,371 and £21,262 per QALY gained respectively.
Conclusion:
Computerised word finding therapy represents a low cost add-on to usual care, but QALY gains and estimates of cost-effectiveness are uncertain. Computerised therapy is more likely to be cost-effective for people with mild or moderate, as opposed to severe, word finding difficulties
Physics Opportunities with the 12 GeV Upgrade at Jefferson Lab
This white paper summarizes the scientific opportunities for utilization of
the upgraded 12 GeV Continuous Electron Beam Accelerator Facility (CEBAF) and
associated experimental equipment at Jefferson Lab. It is based on the 52
proposals recommended for approval by the Jefferson Lab Program Advisory
Committee.The upgraded facility will enable a new experimental program with
substantial discovery potential to address important topics in nuclear,
hadronic, and electroweak physics.Comment: 64 page
A role for XRCC2 gene polymorphisms in breast cancer risk and survival
Background
The XRCC2 gene is a key mediator in the homologous recombination repair of DNA double strand breaks. It is hypothesised that inherited variants in the XRCC2 gene might also affect susceptibility to, and survival from, breast cancer.
Methods
The study genotyped 12 XRCC2 tagging single nucleotide polymorphisms (SNPs) in 1131 breast cancer cases and 1148 controls from the Sheffield Breast Cancer Study (SBCS), and examined their associations with breast cancer risk and survival by estimating ORs and HRs, and their corresponding 95% CIs. Positive findings were further investigated in 860 cases and 869 controls from the Utah Breast Cancer Study (UBCS) and jointly analysed together with available published data for breast cancer risk. The survival findings were further confirmed in studies (8074 cases) from the Breast Cancer Association Consortium (BCAC).
Results
The most significant association with breast cancer risk in the SBCS dataset was the XRCC2 rs3218408 SNP (recessive model p=2.3×10−4, minor allele frequency (MAF)=0.23). This SNP yielded an ORrec of 1.64 (95% CI 1.25 to 2.16) in a two-site analysis of SBCS and UBCS, and a meta-ORrec of 1.33 (95% CI 1.12 to 1.57) when all published data were included. This SNP may mark a rare risk haplotype carried by two in 1000 of the control population. Furthermore, the XRCC2 coding R188H SNP (rs3218536, MAF=0.08) was significantly associated with poor survival, with an increased per-allele HR of 1.58 (95% CI 1.01 to 2.49) in a multivariate analysis. This effect was still evident in a pooled meta-analysis of 8781 breast cancer patients from the BCAC (HR 1.19, 95% CI 1.05 to 1.36; p=0.01).
Conclusions
These findings suggest that XRCC2 SNPs may influence breast cancer risk and survival
Recommended from our members
Developing, monitoring, and reporting of fidelity in aphasia trials : core recommendations from the collaboration of aphasia trialists (CATs) trials for aphasia panel
BACKGROUND Developing, monitoring, and reporting of fidelity are essential and integral components to the design of randomised controlled trials (RCTs) in stroke and aphasia. Treatment fidelity refers to the degree to which an intervention is delivered as intended and is directly related to the quality of the evidence generated by RCTs. Clear documentation of treatment fidelity in trials assists in the evaluation of the clinical implications of potential benefits attributed to the intervention. Consideration of the implementation requirements of a research-based intervention as intended in a clinical context is necessary to achieve similar outcomes for a clinical population. Despite this, treatment fidelity is rarely reported in RCTs of aphasia intervention.
AIM To describe fidelity strategies and develop core recommendations for developing, monitoring, and reporting of fidelity in aphasia intervention RCTs.
SCOPE Relevant conceptual frameworks were considered. The Behaviour Change Consortium comprehensive framework of fidelity was adopted. It includes five areas: study design, training providers, delivery of treatment, treatment receipt, and treatment enactment. We explored fidelity in RCTs with a range of complex aphasia interventions (e.g., ASK, Big CACTUS, COMPARE, FCET2EC, POLAR, SUPERB, and VERSE) and described how different trial design factors (e.g., phase of trial, explanatory vs. pragmatic, number and location of sites, and number and type of treatment providers) influenced the fidelity strategies chosen. Strategies were mapped onto the five areas of the fidelity framework with a detailed exploration of how fidelity criteria were developed, measured, and monitored throughout each trial. This information was synthesised into a set of core recommendations to guide aphasia researchers towards the adequate measurement, capture, and reporting of fidelity within future aphasia intervention studies.
CONCLUSIONS/RECOMMENDATIONS Treatment fidelity should be a core consideration in planning an intervention trial, a concept that goes beyond treatment adherence alone. A range of strategies should be selected depending on the phase and design of the trial being undertaken and appropriate investment of time and costs should be considered
Detector Description and Performance for the First Coincidence Observations between LIGO and GEO
For 17 days in August and September 2002, the LIGO and GEO interferometer
gravitational wave detectors were operated in coincidence to produce their
first data for scientific analysis. Although the detectors were still far from
their design sensitivity levels, the data can be used to place better upper
limits on the flux of gravitational waves incident on the earth than previous
direct measurements. This paper describes the instruments and the data in some
detail, as a companion to analysis papers based on the first data.Comment: 41 pages, 9 figures 17 Sept 03: author list amended, minor editorial
change
A First Search for coincident Gravitational Waves and High Energy Neutrinos using LIGO, Virgo and ANTARES data from 2007
We present the results of the first search for gravitational wave bursts
associated with high energy neutrinos. Together, these messengers could reveal
new, hidden sources that are not observed by conventional photon astronomy,
particularly at high energy. Our search uses neutrinos detected by the
underwater neutrino telescope ANTARES in its 5 line configuration during the
period January - September 2007, which coincided with the fifth and first
science runs of LIGO and Virgo, respectively. The LIGO-Virgo data were analysed
for candidate gravitational-wave signals coincident in time and direction with
the neutrino events. No significant coincident events were observed. We place
limits on the density of joint high energy neutrino - gravitational wave
emission events in the local universe, and compare them with densities of
merger and core-collapse events.Comment: 19 pages, 8 figures, science summary page at
http://www.ligo.org/science/Publication-S5LV_ANTARES/index.php. Public access
area to figures, tables at
https://dcc.ligo.org/cgi-bin/DocDB/ShowDocument?docid=p120000
Recommended from our members
Epstein-Barr virus: clinical and epidemiological revisits and genetic basis of oncogenesis
Epstein-Barr virus (EBV) is classified as a member in the order herpesvirales, family herpesviridae, subfamily gammaherpesvirinae and the genus lymphocytovirus. The virus is an exclusively human pathogen and thus also termed as human herpesvirus 4 (HHV4). It was the first oncogenic virus recognized and has been incriminated in the causation of tumors of both lymphatic and epithelial nature. It was reported in some previous studies that 95% of the population worldwide are serologically positive to the virus. Clinically, EBV primary infection is almost silent, persisting as a life-long asymptomatic latent infection in B cells although it may be responsible for a transient clinical syndrome called infectious mononucleosis. Following reactivation of the virus from latency due to immunocompromised status, EBV was found to be associated with several tumors. EBV linked to oncogenesis as detected in lymphoid tumors such as Burkitt's lymphoma (BL), Hodgkin's disease (HD), post-transplant lymphoproliferative disorders (PTLD) and T-cell lymphomas (e.g. Peripheral T-cell lymphomas; PTCL and Anaplastic large cell lymphomas; ALCL). It is also linked to epithelial tumors such as nasopharyngeal carcinoma (NPC), gastric carcinomas and oral hairy leukoplakia (OHL). In vitro, EBV many studies have demonstrated its ability to transform B cells into lymphoblastoid cell lines (LCLs). Despite these malignancies showing different clinical and epidemiological patterns when studied, genetic studies have suggested that these EBV- associated transformations were characterized generally by low level of virus gene expression with only the latent virus proteins (LVPs) upregulated in both tumors and LCLs. In this review, we summarize some clinical and epidemiological features of EBV- associated tumors. We also discuss how EBV latent genes may lead to oncogenesis in the different clinical malignancie
- …